60 degrees pharmaceuticals, Inc.(SXTP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SXTP 60 degrees pharmaceuticals, Inc.

Market Closed 06-18 16:00:00 EDT

1.64

+0.02

+1.23%

盘后1.64

+0.000.00%

19:28 EDT

High1.71	Low1.57	Vol94.35K
Open1.57	D1 Closing1.62	Amplitude8.64%
Mkt Cap4.36M	Tradable Cap4.08M	Total Shares2.66M
T/O156.19K	T/O Rate3.79%	Tradable Shares2.49M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SXTP","market":"US","secType":"STK","nameCN":"60 degrees pharmaceuticals, Inc.","latestPrice":1.64,"timestamp":1781812800000,"preClose":1.62,"halted":0,"volume":94346,"hourTrading":{"tag":"盘后","latestPrice":1.64,"preClose":1.64,"latestTime":"19:28 EDT","volume":2205,"amount":3615.11,"timestamp":1781825293332,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.012345679012345552,"floatShares":2490200,"shares":2659288,"eps":-10.4652,"marketStatus":"Market Closed","change":0.02,"latestTime":"06-18 16:00:00 EDT","open":1.57,"high":1.71,"low":1.57,"amount":156189.3124008,"amplitude":0.08642,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-10.4652,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782115200000},"marketStatusCode":7,"adr":0,"listingDate":1686801600000,"exchange":"NASDAQ","adjPreClose":1.62,"preHourTrading":{"tag":"盘前","latestPrice":1.56,"preClose":1.62,"latestTime":"08:57 EDT","volume":1102,"amount":1770.5457116,"timestamp":1781787437562,"change":-0.06,"changeRate":-0.037037,"amplitude":0.024691},"postHourTrading":{"tag":"盘后","latestPrice":1.64,"preClose":1.64,"latestTime":"19:28 EDT","volume":2205,"amount":3615.11,"timestamp":1781825293332,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.25410440517769584},"requestUrl":"/m/hq/s/SXTP","defaultTab":"news","newsList":[{"id":"2643778690","title":"60 Degrees Pharma CEO Geoffrey Dow acquires 7,350 common shares worth $10,130.24","url":"https://stock-news.laohu8.com/highlight/detail?id=2643778690","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643778690?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:51","pubTimestamp":1781556684,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals President, CEO, director Geoffrey S. Dow bought 7,350 common shares at USD 1.38 each.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 15, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL4hwKQ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"60 Degrees Pharma CEO Geoffrey Dow acquires 7,350 common shares worth $10,130.24","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642923284","title":"60 Degrees Pharmaceuticals Licenses Patent to Produce Australian Chestnut Extract","url":"https://stock-news.laohu8.com/highlight/detail?id=2642923284","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642923284?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:33","pubTimestamp":1781181200,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals  said Thursday it signed a patent licensing agreement with Florida State University to develop large-scale production methods for Australian chestnut extract, a substance derived from the seeds of the Australian chestnut tree.The company said the extract contains castanospermine, a naturally occurring compound that studies suggest may affect how the body processes carbohydrates and regulates blood sugar levels.The company said the US Food and Drug Administration has provided feedback on its filing seeking approval to market the extract as a dietary supplement ingredient.The FDA and the company are scheduled to meet on July 1 to discuss additional safety information needed for the application, the company said, adding that it plans to submit a revised application to the agency following the meeting.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OZF.AU","IOZ.AU","QFN.AU","OZR.AU","XAO.AU","ZYAU.AU","XKO.AU","XJO.AU","GIVE.AU","GEAR.AU","BK4007","VAS.AU","IMLC.AU","VAP.AU","BBOZ.AU","DACE.AU","BEAR.AU","QRE.AU","SXTP","IISV.AU","EIGA.AU","STW.AU","SLF.AU","E200.AU","IIGF.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642328115","title":"60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement With Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement","url":"https://stock-news.laohu8.com/highlight/detail?id=2642328115","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642328115?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:03","pubTimestamp":1781179380,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA2DB8XQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SXTP","BK4007","SXTPW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642434797","title":"60 Degrees Pharmaceuticals announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642434797","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642434797?lang=en_us&edition=fundamental","pubTime":"2026-06-09 05:15","pubTimestamp":1780953310,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals will hold its 2026 annual shareholder meeting in a virtual, telephone-only format on Aug. 5, 2026.Shareholders will vote on electing five directors, including adding Eric Francois to the board.Other items include expanding the 2022 equity plan by 800,000 shares, plus authorizing a reverse stock split at a 1:5 to 1:10 ratio.Investors will also vote on a management success fee tied to a change of control, strategic transaction, or sale of Arakoda.Additional matters include ratifying RBSM as auditor, plus a possible meeting adjournment to seek more votes on key proposals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL6y9LxY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SXTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640634581","title":"Honeywell's Quantinuum Valued at $17.6 Billion as Shares Rise in Nasdaq Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2640634581","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640634581?lang=en_us&edition=fundamental","pubTime":"2026-06-05 07:02","pubTimestamp":1780614135,"startTime":"0","endTime":"0","summary":"Shares of $Quantinuum(QNT)$ rose 13.3% in their Nasdaq debut, fetching a valuation of $17.63 billion as Honeywell's quantum computing company became the latest to benefit from robust investor demand....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nL4N42C0ZS:1","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Honeywell's Quantinuum Valued at $17.6 Billion as Shares Rise in Nasdaq Debut","news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0868494708.USD","LU0868494617.USD","LU0942090050.USD","BK4534","BK4550","BK4588","IE0034235188.USD","BK4206","BK4170","LU0683600562.USD","SXTP","LU0787776722.HKD","IE00B1BXHZ80.USD","QNT","BK4602","BK4591","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640187394","title":"60 Degrees details tafenoquine priority review voucher strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2640187394","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640187394?lang=en_us&edition=fundamental","pubTime":"2026-06-04 06:14","pubTimestamp":1780524894,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals, Inc. ( ($SXTP) ) has issued an update. 60 Degrees Pharmaceuticals disclosed that it plans to apply for a Commissioner’s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/60-degrees-details-tafenoquine-priority-review-voucher-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/60-degrees-details-tafenoquine-priority-review-voucher-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SXTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640184430","title":"60 Degrees Pharmaceuticals - May Submit Nda for Tafenoquine to FDA Before End of Q1 2028 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2640184430","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640184430?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:58","pubTimestamp":1780520289,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nFWN42B0XY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SXTP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638545535","title":"60 Degrees announces early enrollment of first patient in trial of tafenoquine","url":"https://stock-news.laohu8.com/highlight/detail?id=2638545535","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638545535?lang=en_us&edition=fundamental","pubTime":"2026-05-26 22:57","pubTimestamp":1779807463,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals (SXTP) announced that the first patient of the 2026 tick season has been enrolled in the randomized, double-blind, place...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/60-degrees-announces-early-enrollment-of-first-patient-in-trial-of-tafenoquine-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/60-degrees-announces-early-enrollment-of-first-patient-in-trial-of-tafenoquine-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SXTP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638514509","title":"60 Degrees Pharma enrolls first patient in tafenoquine babesiosis trial in US Northeast hospitals","url":"https://stock-news.laohu8.com/highlight/detail?id=2638514509","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638514509?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:08","pubTimestamp":1779797286,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals enrolled the first 2026 seasonal patient in a placebo-controlled hospital trial testing tafenoquine as an add-on babesiosis treatment.No efficacy results have been presented; an interim analysis is expected once at least 24 patients are enrolled, potentially as soon as early July 2026.Enrollment is running about one month ahead of plan, supporting a faster read on whether tafenoquine improves symptom resolution or parasite clearance.Tafenoquine is marketed as ARAKODA for malaria prevention, not for babesiosis, leaving the program dependent on clinical data to support expansion.A timing update for the interim analyses is planned about 50 days after enrollment is completed.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDLbp1LbD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014021.USD","BK4588","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014039.USD","SXTP","BK4112","LU2210149790.SGD","IE00BN0W2T93.GBP","SG9999014005.SGD","IE00BN0W2W23.USD","NDAQ","BK4585","LU0314104364.USD","BK4007","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638770511","title":"60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized With Babesiosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2638770511","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638770511?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:02","pubTimestamp":1779796920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA1F4MG0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SXTPW","SXTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637311319","title":"60 Degrees Pharm Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2637311319","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637311319?lang=en_us&edition=fundamental","pubTime":"2026-05-22 20:06","pubTimestamp":1779451560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SXTP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 22, 2026 08:06 ET (12:06 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SXTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637802730","title":"U.S. RESEARCH ROUNDUP-Analog Devices, Intuit, Nvidia","url":"https://stock-news.laohu8.com/highlight/detail?id=2637802730","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637802730?lang=en_us&edition=fundamental","pubTime":"2026-05-21 14:42","pubTimestamp":1779345750,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Analog Devices, Intuit, NvidiaMay 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Analog Device","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"5d07a255fa50ca2b85b03d26b4c3c2c1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nL4N41Y0I2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07388","NVDQ","NVDB","GTM","LU1548497426.USD","TJX","SNVD.UK","INTU","KO","NVDY","GLXY","NVDG","COR","ANV","GLXU","NVD","TOL","KEYS","NVIW.SI","GLGG","LOW","3NVD.UK","2NVD.UK","HK0000304797.USD","DIPS","NVD2.UK","NVDS.UK","FLYW","ADI","NVDD","NVDW","NVDX","ELF","NVDO","NVYY","NVDS","NVDL","SG9999014567.USD","IE00B19Z9P08.USD","NVDA","NVD3.UK","IE00B4YYXB79.USD","NVDU","NVII","LU0124384867.USD","SXTP","IMVT","HPE","07788","TGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637369805","title":"60 Degrees Pharmaceuticals Inc : H.c. Wainwright Cuts to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2637369805","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637369805?lang=en_us&edition=fundamental","pubTime":"2026-05-21 11:16","pubTimestamp":1779333397,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nFWN41X0ST:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SXTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637824891","title":"60 Degrees Pharm Cut to Neutral From Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2637824891","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637824891?lang=en_us&edition=fundamental","pubTime":"2026-05-21 01:13","pubTimestamp":1779297180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SXTP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 20, 2026 13:13 ET (17:13 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637829420","title":"60 Degrees Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2637829420","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637829420?lang=en_us&edition=fundamental","pubTime":"2026-05-20 23:55","pubTimestamp":1779292536,"startTime":"0","endTime":"0","summary":"H.C. Wainwright downgraded 60 Degrees Pharmaceuticals (SXTP) to Neutral from Buy. Published first on TheFly – the ultimate source for real-time, ma...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/60-degrees-pharmaceuticals-downgraded-to-neutral-from-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/60-degrees-pharmaceuticals-downgraded-to-neutral-from-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SXTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636867051","title":"60 Degrees Pharma director Eric Francois files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2636867051","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636867051?lang=en_us&edition=fundamental","pubTime":"2026-05-20 06:14","pubTimestamp":1779228893,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals director Eric Francois filed an initial Form 3 statement of beneficial ownership dated May 13.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL8bMmJg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SXTP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636009923","title":"60 Degrees Pharma appoints Eric Francois to board","url":"https://stock-news.laohu8.com/highlight/detail?id=2636009923","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636009923?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:33","pubTimestamp":1779136427,"startTime":"0","endTime":"0","summary":"60 Degrees Pharmaceuticals appointed Eric Francois to its board on May 13, 2026, effective immediately.Francois is an independent director at CERo Therapeutics Holdings.He previously served as a managing director in healthcare investment banking at Raymond James and Credit Suisse.He was also CFO of SCYNEXIS, overseeing finance and corporate development through its FDA approval and commercial launch.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information conta","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL1zNXxB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BGHQF748.EUR","SXTP","CERO","RJF","IE00B64PRP62.GBP","LU1804176565.USD","LU1363072403.SGD","SCYX","BK4139","BK4127","IE00B3QW5Z07.USD","BK4588","LU0971096721.USD","LU2265009873.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635576080","title":"60 Degrees Q1 EPS $(1.28) Misses $(0.76) Estimate, Sales $76.377K Miss $435.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635576080","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635576080?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:29","pubTimestamp":1778851747,"startTime":"0","endTime":"0","summary":"60 Degrees (NASDAQ:SXTP) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(0.76) by 68.42 percent. This is a 79.52 percent increase over losses of $(6.25) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52596202/60-degrees-q1-eps-1-28-misses-0-76-estimate-sales-76-377k-miss-435-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SXTP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635825760","title":"60 Degrees Pharmaceuticals Q1 Operating Expenses USD 2.17 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635825760","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635825760?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:42","pubTimestamp":1778848920,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLXFA075B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SXTP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635408257","title":"60 Degrees Pharmaceuticals Q1 Net Income USD -2.21 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635408257","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635408257?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:42","pubTimestamp":1778848920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLXFA075B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","SXTP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.60degreespharma.com","stockEarnings":[{"period":"1week","weight":0.1884},{"period":"1month","weight":0.1631},{"period":"3month","weight":-0.159},{"period":"6month","weight":-0.4598},{"period":"1year","weight":-0.8102},{"period":"ytd","weight":-0.1934}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is based in Washington, District Of Columbia.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.040319},{"month":2,"riseRate":0,"avgChangeRate":-0.262735},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.15171},{"month":4,"riseRate":0.333333,"avgChangeRate":0.079946},{"month":5,"riseRate":0.333333,"avgChangeRate":0.058798},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.038209},{"month":7,"riseRate":0,"avgChangeRate":-0.425682},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.188581},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.16297},{"month":10,"riseRate":0,"avgChangeRate":-0.229986},{"month":11,"riseRate":0.666667,"avgChangeRate":0.078807},{"month":12,"riseRate":0.666667,"avgChangeRate":0.11386}],"exchange":"NASDAQ","name":"60 degrees pharmaceuticals, Inc.","nameEN":"60 degrees pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"60 degrees pharmaceuticals, Inc.(SXTP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest 60 degrees pharmaceuticals, Inc.(SXTP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"60 degrees pharmaceuticals, Inc.,SXTP,60 degrees pharmaceuticals, Inc.股票,60 degrees pharmaceuticals, Inc.股票老虎,60 degrees pharmaceuticals, Inc.股票老虎国际,60 degrees pharmaceuticals, Inc.行情,60 degrees pharmaceuticals, Inc.股票行情,60 degrees pharmaceuticals, Inc.股价,60 degrees pharmaceuticals, Inc.股市,60 degrees pharmaceuticals, Inc.股票价格,60 degrees pharmaceuticals, Inc.股票交易,60 degrees pharmaceuticals, Inc.股票购买,60 degrees pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"60 degrees pharmaceuticals, Inc.(SXTP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest 60 degrees pharmaceuticals, Inc.(SXTP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction